Acta Neuropathologica

, 122:651 | Cite as

Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma

  • Jens SchittenhelmEmail author
  • Michel Mittelbronn
  • Richard Meyermann
  • Arthur Melms
  • Marcos Tatagiba
  • David Capper

Identification of mutations affecting codon 132 of the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) in astrocytomas, oligodendrogliomas and secondary glioblastomas has influenced current concepts of diffuse gliomas. A recent study published in this journal demonstrated that in anaplastic astrocytomas and glioblastomas IDH1 mutation status better reflected patient prognosis than histological diagnosis according to the current WHO classification system [3]. Even more intriguingly, patients with IDH1 wild type anaplastic astrocytomas demonstrated not only shorter overall survival (OS) when compared to IDH1 mutant anaplastic astrocytoma patients, but even survived shorter than patients with IDH1 mutant glioblastoma. Results were based on data from the NOA-04 trial [7] and the German Glioma Network [6].

Here, we screened an independent tumor dataset of patients at the Neurooncology Center (Comprehensive Cancer Center Tübingen) consisting of 281 gliomas that were not enrolled in the...


Astrocytoma Anaplastic Astrocytoma MGMT Promoter Methylation MGMT Promoter Methylation Status IDH1 Wild Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254PubMedCrossRefGoogle Scholar
  2. 2.
    Hartmann C, Hentschel B, Tatagiba M et al (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17:4588–4599PubMedCrossRefGoogle Scholar
  3. 3.
    Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRefGoogle Scholar
  4. 4.
    Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474PubMedCrossRefGoogle Scholar
  5. 5.
    Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729PubMedCrossRefGoogle Scholar
  6. 6.
    Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750PubMedCrossRefGoogle Scholar
  7. 7.
    Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Jens Schittenhelm
    • 1
    Email author
  • Michel Mittelbronn
    • 2
  • Richard Meyermann
    • 1
  • Arthur Melms
    • 3
  • Marcos Tatagiba
    • 4
  • David Capper
    • 5
  1. 1.Department of Neuropathology, Institute of Pathology and NeuropathologyUniversity of TubingenTübingenGermany
  2. 2.Neurological Institute, Edinger InstituteUniversity of FrankfurtFrankfurtGermany
  3. 3.Department of NeurologyUniversity of TubingenTübingenGermany
  4. 4.Department of NeurosurgeryUniversity of TubingenTübingenGermany
  5. 5.Department of Neuropathology, Institute of PathologyRuprecht-Karls-University HeidelbergHeidelbergGermany

Personalised recommendations